Erlotinib Treatment Beyond Progression in EGFR Mutant NSCLC

NCT02064491 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

18

Enrollment

OTHER

Sponsor class

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG: Erlotinib
DRUG: Chemotherapy

Sponsor

Finnish Lung Cancer Group

Collaborators

[object Object]